- Home
- DERM vs BYSI Comparison
DERM vs BYSI Comparison
Compare DERM & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- BYSI
- Stock Information
- Founded
- DERM 2014
- BYSI 2010
- Country
- DERM United States
- BYSI United States
- Employees
- DERM N/A
- BYSI N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- DERM Health Care
- BYSI Health Care
- Exchange
- DERM Nasdaq
- BYSI Nasdaq
- Market Cap
- DERM 124.4M
- BYSI 99.5M
- IPO Year
- DERM 2021
- BYSI 2017
- Fundamental
- Price
- DERM $6.02
- BYSI $2.39
- Analyst Decision
- DERM Strong Buy
- BYSI
- Analyst Count
- DERM 3
- BYSI 0
- Target Price
- DERM $9.50
- BYSI N/A
- AVG Volume (30 Days)
- DERM 60.8K
- BYSI 24.9K
- Earning Date
- DERM 11-05-2024
- BYSI 01-01-0001
- Dividend Yield
- DERM N/A
- BYSI N/A
- EPS Growth
- DERM N/A
- BYSI N/A
- EPS
- DERM 0.04
- BYSI N/A
- Revenue
- DERM $77,681,000.00
- BYSI $1,876,000.00
- Revenue This Year
- DERM N/A
- BYSI N/A
- Revenue Next Year
- DERM $50.57
- BYSI N/A
- P/E Ratio
- DERM $135.64
- BYSI N/A
- Revenue Growth
- DERM 26.38
- BYSI 21.03
- 52 Week Low
- DERM $2.85
- BYSI $0.78
- 52 Week High
- DERM $8.11
- BYSI $4.00
- Technical
- Relative Strength Index (RSI)
- DERM 56.84
- BYSI 55.53
- Support Level
- DERM $5.56
- BYSI $2.27
- Resistance Level
- DERM $6.17
- BYSI $2.53
- Average True Range (ATR)
- DERM 0.52
- BYSI 0.19
- MACD
- DERM -0.02
- BYSI -0.00
- Stochastic Oscillator
- DERM 40.41
- BYSI 53.33
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.